brexucabtagene autoleucel
(brek-suh-KAB-tuh-jeen AW-toh-LOO-sel)
A drug used to treat adults with mantle cell lymphoma or B-cell acute lymphoblastic leukemia that came back or did not get better after other treatment. It is also being studied in the treatment of other types of cancer. Brexucabtagene autoleucel is made using a patient’s T cells (a type of immune system cell). A gene for a special receptor called chimeric antigen receptor (CAR) is added to the T cells in the laboratory. These changed T cells called CAR T cells are grown in large numbers in the laboratory and given to the patient by infusion. Brexucabtagene autoleucel binds to a protein called CD19, which is found on some lymphoma cells and leukemia cells. This helps the body’s immune system kill cancer cells. Brexucabtagene autoleucel is a type of CAR T-cell therapy. Also called Tecartus.
More Information
Enlarge this image in new windowCAR T-cell therapy. A type of treatment in which a patient’s T cells (a type of immune cell) are changed in the laboratory so they will bind to cancer cells and kill them. Blood from a vein in the patient’s arm flows through a tube to an apheresis machine (not shown), which removes the white blood cells, including the T cells, and sends the rest of the blood back to the patient. Then, the gene for a special receptor called a chimeric antigen receptor (CAR) is inserted into the T cells in the laboratory. Millions of the CAR T cells are grown in the laboratory and then given to the patient by infusion. The CAR T cells are able to bind to an antigen on the cancer cells and kill them.